Global Cord Blood Corporation Acquires Cellenkos, Inc.
April 29, 2022
Global Cord Blood Corporation (GCBC) agreed to acquire 100% of clinical-stage biotech Cellenkos, Inc., and worldwide rights to most of its products (excluding those under an Incyte collaboration). The transaction consideration includes approximately 125 million new shares (as-converted) valued at $11 per share plus $664 million in cash; GCBC said the acquisition expands its capabilities into allogeneic T-reg cell therapies and supports global commercialization and R&D.
- Buyers
- Global Cord Blood Corporation
- Targets
- Cellenkos, Inc.
- Sellers
- Holders of approximately 95% of Cellenkos outstanding equity interest, GM Precision Medicine (BVI) Limited
- Industry
- Biotechnology
- Location
- Texas, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
GC Corp Signs Definitive Agreement to Acquire BioCentriq, Inc.
April 19, 2022
Healthcare Services
GC corp., the holding (system) company for the GC group in South Korea, signed a definitive agreement to acquire 100% of the shares of BioCentriq, Inc. BioCentriq is a US-based CDMO focused on scalable cell and gene technology development and cGMP-grade clinical manufacturing.
-
Pfizer Acquires Global Blood Therapeutics (GBT) for $5.4 Billion
August 8, 2022
Biotechnology
Pfizer entered into a definitive agreement to acquire Global Blood Therapeutics (GBT), paying $68.50 per share in cash for an enterprise value of about $5.4 billion. The deal adds GBT’s sickle cell disease portfolio, including Oxbryta (voxelotor), along with clinical pipeline assets such as GBT021601 (GBT601) and inclacumab.
-
Lonza AG Acquires PharmaCell BV
June 1, 2017
Biotechnology
Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
GBA Group Acquires KaLy-Cell SAS
September 5, 2022
Biotechnology
GBA Group has acquired French contract research organization KaLy-Cell SAS, marking the group's market entry into France and expanding its European pharmaceutical network. KaLy-Cell, founded in 2003 as a spin-off from the University of Bourgogne Franche-Comté and headquartered in Plobsheim, provides hepatocyte-based in vitro contract research and safety testing services for pharmaceuticals, agrochemicals and cosmetics.
-
Gilead Sciences To Acquire Arcellx for $7.8 Billion to Strengthen CAR T-Cell Portfolio
February 21, 2026
Biotechnology
Gilead Sciences entered into a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a contingent value right of $5 per share, implying an equity value of about $7.8 billion. The deal is designed to give Gilead full control of Arcellx’s anito-cel (anito-cabtagene autoleucel) BCMA-directed CAR T therapy, eliminating profit-sharing and related payments while accelerating development and commercialization.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.